Aviad Rotholz

Procedural and Hemodynamic Outcomes of Contemporary Self-Expanding Valves for Transcatheter Aortic Valve Replacement: A Multicenter Comparison From the AMTRAC Registry

Amos Levi, Yeela Talmor‐Barkan, Marco Barbanti, Sofia Sammartino et autres

Background Comparative data among contemporary self-expanding transcatheter heart valve designs remain limited. We compared clinical and hemodynamic outcomes following transcatheter aortic valve replacement (TAVR) using two leading contemporary platforms. Methods This multicenter cohort study utilized the AMTRAC registry to evaluate consecutive patients …

il, it, dk, es, si, de, ie, gb (code pays fourni par la source)

The Safety Profile of Ticagrelor among Older Adults (Age ≥75 years): A Pharmacovigilance Analysis

Inbar Yacoby-Halevi, Boris Kruchin, Chen Gadot, Dmitri Guz et autres

INTRODUCTION: Ticagrelor is a widely used potent P2Y12 inhibitor in patients aged ≥75 years with acute coronary syndromes. Despite its widespread use, data on ticagrelor's safety in older adults remain limited. METHODS: We performed a retrospective pharmacovigilance analysis using the FDA Adverse …

il, us (code pays fourni par la source)

Sex Differences in Long-Term Outcomes of Left Atrial Appendage Closure—Analysis from the LEADER Registry

Aviad Rotholz, Hagai Itach, Roi Ferman, Tsahi T. Lerman et autres

Background: Percutaneous left atrial appendage closure (LAAC) provides an alternative to oral anticoagulation (OAC) in atrial fibrillation (AF) patients who are at high bleeding risk. Prior studies have suggested sex-related differences in procedural outcomes, with women demonstrating higher peri-procedural complication rates. Data …

il (code pays fourni par la source)

Procedural and Prognostic Implications of Guide Extension Catheter Use During Percutaneous Coronary Intervention: A Retrospective Cohort Study

Edward Itelman, Aviad Rotholz, Tamir Bental, Tsahi T. Lerman et autres

BACKGROUND: Guide extension catheters (GECs) have become an essential adjunctive tool in complex percutaneous coronary interventions (PCIs). GECs provide additional catheter support and stability, enhancing device deliverability. AIMS: Our study aims to evaluate the technical and prognostic significance of the use of …

il (code pays fourni par la source)

Comparison of left atrial appendage occlusion with medical treatment for non-valvular atrial fibrillation: systematic review, network and reconstructed individual patient data meta-analysis

Tsahi T. Lerman, Roy Hershenson, Noam Greenberg, Mark Kheifets et autres

il, us (code pays fourni par la source)

Sex differences in the treatment with PCSK9 monoclonal antibodies- real world experience from a dedicated preventive cardiology clinic

Lital Hodeda, Alon Eisen, Aviad Rotholz, Ran Kornowski et autres

Purpose Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies (PCSK9 mAb) lower low-density lipoprotein cholesterol (LDL-C) levels and reduce atherosclerotic cardiovascular disease (ASCVD). Data regarding sex differences in PCSK9 mAb treatment remain lacking. This study examines sex differences in patients' characteristics, indications, efficacy, …

il, us (code pays fourni par la source)

Impact of Transport Method in Patients With ST‐Segment–Elevation Myocardial Infarction on Patient Outcomes: Real‐World Data From the ACSIS Registry

Aviad Rotholz, Tsahi T. Lerman, Jenan Awesat, Alon Eisen et autres

Background The ambulance system is vital for the early management of patients with ST‐segment–elevation myocardial infarction, reducing delays in diagnosis and treatment. This study examined the impact of transport mode on reperfusion therapy and mortality among patients with ST‐segment–elevation myocardial infarction from …

il, us (code pays fourni par la source)

Circulating Endothelial Progenitor Cells in Patients with Established Cardiovascular Disease Treated with PCSK9 Monoclonal Antibodies

Chen Gurevitz, Osnat Itzhaki Ben Zadok, Dorit Leshem‐Lev, Lital Hodeda et autres

• Circulating endothelial progenitor cells (cEPCs) have a crucial role in vascular repair. • Among patients with cardiovascular disease PCSK9 mAb initiation is associated with an increase in cEPCs levels and function. • These findings persist in both evolocumab and alirocumab. • …

il, us (code pays fourni par la source)

Gender differences in the treatment with PCSK9 monoclonal antibodies real world experience from a dedicated prevention clinic

Lital Hodeda, Edo Y. Birati, Aviad Rotholz, Alon Eisen

Abstract Background Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies (PCSK9 mAb) lower low-density lipoprotein cholesterol (LDL-C) levels and reduce atherosclerotic cardiovascular disease (ASCVD). There are gender differences in PCSK9 biological characteristics, which are not properly addressed in current data. Purpose Examining gender …

il (code pays fourni par la source)

Clinical Outcomes of FFRangio-Guided Treatment for Coronary Artery Disease

Guy Witberg, Tamir Bental, Amos Levi, Yeela Talmor‐Barkan et autres